Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! Today, we discuss why a cell therapy stalwart is pivoting, and why a Feng Zhang startup is laying off a quarter of its staff. Also, Novartis is using some of its GLP-1 windfall to invest in Flagship Pioneering startups in the cardiometabolic space.

The need-to-know this morning

We’ve got a news lull ahead of next week’s all-encompassing J.P. Morgan Healthcare Conference in San Francisco. Inhale. Relax. Exhale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In